on epicardial vessel diameter and coronary sinus oxygen saturation were investigated in 13 patients who had angiographically normal coronary arteries. The dose of substance P ranged from 2.8 to 89.6 pmol/min, starting at 2.8 pmol/min and rising by doubling increments. All infusions were performed for 2-minute periods. Epicardial vessel diameter was measured by a computerized analysis system (CAAs) of the angiogram performed at the end of each infusion period. Coronary sinus oxygen saturation (CSo2) was measured continuously by a fiber-optic oximeter catheter in the coronary sinus. A reduction of arterial pressure, indicative of a systemic effect of substance P, occurred only when infusions were 44.8 pmol/min or more. At considerably smaller dosages, a dose-dependent increase in the left anterior descending artery diameter was seen with substance P; maximal dilation occurred at a dosage of 11.2 pmol/min. The percent increase in vessel diameter for this dosage was 29.4±19.8% (mean±+SD) at the distal site of analysis and 16.7±10% at the proximal site of analysis. CSo2 rose in a dose-dependent manner and was maximal at a dosage of 11.2 pmol/min, which caused a 14.6±7.2% 02 rise above the preinfusion saturation of 43.5±11.1% 02. As the heart rate-blood pressure double product showed no change, it is argued that these changes in CSo2 probably reflect rises in coronary flow that were seen with dosages of substance P without systemic effect. In three patients, preconstriction induced by ergonovine was reversed by substance P infusions, which produced a degree of dilation equivalent to that of isosorbide dinitrate. We conclude that substance P at very small dosages, which are without peripheral effects, causes in vivo epicardial coronary artery dilatation as well as resistive vessel dilatation in humans. (Circulation 1989;80:475-484) T he control of coronary blood flow and epicardial vessel size is a delicate mechanism that involves the interplay of dilator and constrictor forces, which may be both humoral and neural. temr, substance P is found in sensory neurons,6 the vagus,7 and some sympathetic ganglia.8 Immunohistochemistry has shown an abundance of substance P-containing neurons in the perivascular nerves of many animals.9'10 Substance P has been found in some quantity in the guinea pig heart and in perivascular regions of small arterioles in human heart specimens."1 Substance P was first discovered as a result of its depressor action.12 It is a very potent vasodilator in many species, including humans where it causes a drop in peripheral resistance after intravenous infusion13 and vasodilation of the forearm when infused into the brachial artery.'4"15 The action of the peptide on the coronary circulation is not clear; there is little effect in the guinea pig,16 and a small constrictor action in the rat'7 but a dilator effect in the dog18 and the pig. 9 Substance P now must be considered within the context of the tachykinin system of which it is only one peptide of a family that includes neurokinins A 
and B. These differ in their rank order of potency between species, but in humans the cutaneous responses show that substance P is the most potent.20
Methods
The study protocol was approved by the Research and Ethical Committees of Hammersmith Hospital.
Thirteen patients (11 men and two women; mean age, 46 years; range, 24-75 years) were studied after routine Judkins coronary arteriography. All patients were investigated for assessment of their chest pain, which was not typical of angina pectoris, and they were found to have negative exercise tests at high workloads. Drug therapy of any form had been discontinued for at least 48 hours before the studies. The coronary arteriograms were either normal or showed only very minor irregularities in the vessel wall.
On completion of the diagnostic angiograms of both coronary arteries with Omnipaque 350 contrast medium, a 4F fiber-optic oximeter catheter (in vivo combimeter system IVS 4000, Schwarzer, Picker Instruments) was advanced from the left subclavian vein to the coronary sinus. The left coronary artery was then reintubated with a 7F high-flow left Judkins catheter of the appropriate size. A baseline angiogram was performed in the projection best displaying the left coronary anatomy as determined from the diagnostic films. The high-resolution 12.7-cm image intensifier (Optimus M200 Phillips) was not moved from this point on.
In one patient, in addition to the introduction of the coronary sinus oximeter catheter, a Sentron micromanometer-tipped 7F pigtail catheter (Cordis) was advanced to the left ventricle. The first differential of the left ventricular pressure with time was used to assess myocardial contractility.
A 1-mM substance P (Cambridge Research Biochemicals) solution in 10% acetic acid was then diluted in normal saline to stock solutions for storage at a concentration of 2x 10-M. All samples were frozen at -20°C. All further dilutions were made with normal saline. Aliquots of the peptide were sent for sterility and toxicity testing. Matching samples of the acetic acid solution were prepared and frozen, and a dilution corresponding to that made for the highest concentration of peptide was used for the control infusion studies.
Vehicle solutions or peptide were infused at a rate of 2 ml/min and lasted for 2 minutes. Throughout this period, blood pressure and heart rate were recorded; in 11 patients, coronary sinus oxygen saturation (CSo2) was also monitored. In one patient, left ventricular dP/dt was recorded. After each infusion, another coronary arteriogram was performed. Vehicle infusions were performed in all but one patient and occurred either before (eight patients) or after (four patients) the peptide infusions. A maximum of five repeated-vehicle infusions were performed, but because this added greatly to the time and discomfort of the procedure in some patients, the number was reduced. All patients received substance P infusions and started at a dosage of 2.8 pmol/min. This was increased by doubling dose increments (while keeping the rate of infusion constant) up to a maximum of 89.6 pmol/ min. Not all patients received the highest dosages because of peripheral vasodilatation or fatigue. In three patients, ergonovine was administered after these infusion studies, by intracoronary injection in increasing incremental doses (5, 10, 15 , Ltg) to reach a total cumulative dose of 50 ,ug ergonovine. Then, another angiogram was performed, followed by an infusion of substance P at 44 pmol/min. Angiograms were taken after each infusion and in two of these patients, after an additional 8 minutes after discontinuation of the peptide. On completion of this part of the study, 2 mg i.c. isosorbide dinitrate was administered to all three patients, and a final angiogram was performed 1 minute later.
Quantitative Angiographic Analysis
Coronary artery luminal diameters were measured by an automated edge contour detection computer analysis system (Cardiovascular Angiography Analysis System [cAAs], Pie Data Medical). From end-diastolic film frames, specific proximal and distal segments of the left anterior descending coronary artery were defined by distances from side branches. The size of the coronary catheter was used for calibration of the image in millimeters, and correction was made for radiographic pincushion distortion. The degree of dilatation seen and the incremental dose increases in the protocol made completely blinded observation impractical. However, 20 randomly selected film frames were reanalyzed by a blinded observer, and measurement was highly reproducible: r=0.995 and p=NS between observations.
Statistical Analysis
All values are given as mean-t+1 SD; when shown graphically, mean+ 1 SEM is used. Statistical analysis was performed by repeated-measures analysis of variance with the STATGRAPHIC package (version 2.1, Statistical Graphics Corporation); this program allows for missing values in the data.
Results
The infusion studies were well tolerated and produced no side effects. None of the patients experienced any chest pain during any stage of any infusion. No alteration in the surface electrocardiogram was seen.
Epicardial Vessel Dilatation
Infusions of vehicle caused little change in left anterior descending coronary artery diameter. There was no trend toward either dilatation or constriction after as many as five repeated infusions of vehicle with their corresponding angiograms. The change in diameter of the left anterior descending coronary artery for all the infusions grouped together was -1.5+7% (mean ±SD; NS) at the proximal site and +2.2 13.1% (mean+SD; NS) at the distal site.
Substance P caused a dose-dependent increase in left anterior descending coronary artery diameter at both proximal and distal points (Figures 1 and 2 ). Figure 2 shows the percentage increase in diameter elicited by the increasing dosages of substance P. The dose-dependent rise was highly significant (p<0.001) for both sites measured when compared with the vehicle infusion. Figure 2 shows that the maximal response was achieved by 11 (Figure 3 ), which is in keeping with the longer action of ergonovine compared with substance P. Isosorbide dinitrate (2 mg) was given via the intracoronary route and reestablished vasodilatation, but this was not substantially greater than that seen with substance P (Figure 3 ). Coronary Sinus Oxygen Saturation Changes Table 1 shows CSo2 changes with vehicle and peptide infusions. Small, nonsignificant rises were seen with vehicle solutions (3.0±3.8% 02). Substance P caused a further rise in CSo2, which was dose dependent, and these changes were highly significant compared with control (p <0.001) ( Figure  4 ). These changes were maximal by 11.2 pmol/min substance P, which caused a rise in CSo2 of 14.6±7.2% 02. Not all patients responded uniformly. Table 2 shows the data from all patients who had CSo2 recordings. The elevations in CSo2 were quite variable between patients but were dose dependent within patients. One patient (1, Table 2) did not respond at all to the peptide, whereas the appropriate changes in CSo2 were observed with angiography. The reason for the complete lack of CSo2 changes in this patient is unclear.
The rise in CSo2 takes -8 seconds to move from basal to the maximum achieved. A tracing obtained from one of the patients is shown in Figure 6 . The CSo2 response occurs promptly after a delay result- The smaller ofthepair represents the distal site. After the constriction induced by ergonovine, all three patients received a 44.8 pmol/min substance P infusion. Two patients had angiograms taken 8 minutes after discontinuation of the substance P, and all three were then given 2 mg i. c. isosorbide dinitrate.
ing from the catheter dead space volume. In all patients, CSo2 response peaked early and was beginning to fall by the end of the 2-minute infusion. One patient had a prolonged infusion (7 minutes) of 22.4 pmol/min substance P. In this patient, a rise of 10% 02 in CSo2 was seen at the end of the first and second minutes. This response then began to decline, but a 4% 02 elevation above baseline was still present at 7 minutes. On discontinuation of the infusion, the CSo2 saturation returned almost immediately to baseline.
Hemodynamic Effects
Any vasodilator that is not immediately inactivated on passage through the organ into which it is infused may give rise to peripheral vasodilatation and thus complicate the interpretation of the changes seen. To assess this, the data in 12 patients was analyzed for the maximum fall in mean blood pressure during the infusion period. The fall seen with vehicle infusions was used for statistical comparison. Multiple-range analysis of the blood pressure falls for each dosage of substance P showed that a statistically significant and progressive reduction in mean systemic blood pressure was only achieved at a dosage of 44.8 pmol/min (p<0.05) and more ( Figure 5 ). The dosage of 44.8 pmol/min caused an 11.9±7.7 mm Hg fall; this increased to 17.4±13.0 mm Hg for the 89.6 pmol/min dosage. Figure 6 shows the recording from a patient infused with 89.6 pmol/min substance P. This causes a significant reduction in systemic blood pressure as well as a rise in CSo2. The two events are clearly separated in time, with the change in CSo2 occurring before any peripheral hemodynamic effects; this is presumably the result of the peptide entering the systemic circulation. Clearly, the changes in CSo2 are not a result of the peripheral effects.
The heart rate-systolic blood pressure double product correlates with myocardial oxygen consumption when the inotropic status of the heart does not change.21 This was, therefore, examined at the basal state, the time of maximum rise in CSo2, and the time of maximum fall in mean blood pressure. changes seen. The heart rate-systolic blood pressure double product at the time of maximum rise in CSo2 and fall in blood pressure is plotted in Figure  4 . Analysis of variance reveals no significant difference (at the 95% confidence level) between any of these values.
To support the prediction from these results that the work of the heart was not being altered by substance P. a study of one patient was conducted with a micromanometer-tipped left ventricle catheter. Despite sustaining very large rises in CSo2 (patient 11, Table 2 ), no changes in dP/dt were seen during any infusion. A compressed recording of all the infusions performed in this patient is shown in Figure 7 where the dose-dependent rises in CSo2 are unassociated with changes in dP/dt. The characteristic negative inotropic effect of the radiographic contrast media is seen with each angiogram after the infusions. It is, therefore, probable that substance P does not change myocardial contractility.
Discussion
These results demonstrate that the vasodilator peptide substance P is an efficacious dilator of epicardial vessels in humans, as observed in the dog18 and pig,19 but at variance with findings in the rat17 and the guinea pig. 16 In addition, in humans, our data suggest that substance P is a modest dilator of resistance vessels because a rise in CSo2 was found in the absence of any changes in heart activity within a group of patients who had normal epicardial vessels. These effects were a direct action of the peptide on the coronary circulation and not a result of its effects on the systemic vasculature as the maximal increases in CSo2 and epicardial vessel diameter occurred at 11.2 pmol/min substance P, a dosage that caused no alteration in peripheral blood pressure.
Coronary blood flow was not measured directly in our study; only the CSo2 changes in response to the peptide infusions were recorded. When considering whether a change in CSo2 reflects an alteration in coronary blood flow, by application of the Fick principle, it is axomatic that cardiac function, and hence the MVo2, remain constant. In such a study as this, the most likely disturbance that will alter the work of the heart and negate such an assumption is the influence of peripheral hemodynamic eflects. Our study shows clearly that maximal changes in 
.. 27 29 Each parameter is recorded in the basal state (immediately preinfusion), at the time of maximal rise in coronary sinus oxygen saturation (CSo2), and at the point of maximal reduction in mean blood pressure.
HR, heart rate; AOS, aortic systolic pressure; BP, blood pressure; NF, no fall; NR, no rise; events: V, vehicle infusion; 2.8, 2.8 pmol/min substance P infusion.
CSo2 were achieved with dosages well below those affecting peripheral resistance. In addition, when there was a reduction in systemic blood pressure at high dosages of the peptide, this occurred after any changes in CSo2 ( Figure 6 ). As a reflection of MVo2, the heart rate-systolic blood pressure double product was analyzed at two time points: the time of maximal rise of CSo2 and the time of maximum peripheral hemodynamic disturbance. At neither time was there any alteration in this parameter, which reflects the load and heart rate determinants of MVo2.21 Therefore, to account for these changes in CSo2 by anything other than a real change in coronary flow, either a change in myocardial contractility or left ventricular volume must occur in the absence of changes in the double product. Large positive ionotropic changes are required to increase MVo2; Graham et Concomitant dilatation of resistance and epicardial vessels, as has been inferred from the data we report for substance P. is not always found with coronary vasodilators26-28; nitrates tend to dilate conductive vessels and cause slight and transient increases in coronary flow, whereas dipyridamole and adenosine increase flow without changes in the large vessels. For these two groups of agents, the regional differences extend to their effects on the action potentials of the smooth muscle cells from the arteries of large and small coronary arteries.29 One possibility is that epicardial coronary dilatation follows on an increase in flow, the phenomenon first described in the femoral artery.30 In dogs, this has also been shown to occur in the coronary circulation,31 but the changes in flow must be large to produce small changes in epicardial vessels. We show that substance P causes substantial epicardial dilatation in conscious humans of a degree comparable with nitrates. The changes in flow, however, are probably modest; this makes ascending dilatation, or flow-induced changes, responsible for the epicardial dilatation unlikely.
Vasodilator agents must now be divided into those that require an intact endothelium and those that do not. 32 These regional differences between substances with apparently similar mechanisms of dilatation may be explained by differing receptor distribution, differing membrane transduction mechanisms, or differing types of endothelium-derived relaxing factors. In addition,7 the large changes in coronary flow seen with acetylcholine with only small changes in epicardial diameter37 again suggest that the alteration in epicardial vessels seen with substance P are not a consequence of increased flow. The amounts of substance P used in our study are very small and cause substantial changes in epicardial coronary diameter as well as modest increases in coronary blood flow. The dosages 2.8-11.2 pmol/ min elicited the dose-dependent effects; these were equivalent to 3.8-15 ng/min substance P. By comparison with the amounts of other agents required to cause epicardial coronary dilatation, substance P is the most pharmacologically potent compound known to date-calcitonin gene-related peptide shows half-maximal dilatation at 15 pmol/minj4 whereas 2.8 pmol/min substance P produced this response.
The observation that substance P immunoreactivity can be demonstrated in the human heart'1 combined with the observations reported here prompt speculation as to the possible physiologic role of substance P. Some studies have measured the absolute amount of substance P within cardiac tissues, including the coronary arteries of dogs.38 These observations are fraught with interpretation difficulties because the bioavailable amounts of a neurotransmitter within a piece of tissue are a function of its rate of biosynthesis and rate of transport within the neurons as well as of the rate of release from nerve terminals and the rate of destruction. Substance P is an 11-amino-acid peptide that is destroyed by cell surface-bound peptidases that cleave the molecule at several sites and generate a number of fragments that may or may not have biologic activity but will retain a degree of immunoreactivity and thus complicate assays measuring the peptide in plasma or elsewhere. Therefore, the physiologic relevance of these observations remains to be identified and will require the use of highly specific peptide-blocking agents as well as a more detailed knowledge of the central connections of the substance P-containing neurons. It is, however, clear that the changes that we report were achieved with very small amounts of the peptide that would have been further diluted by the left coronary blood flow and were observed without blockade of the endogenous breakdown systems. It is concluded from this pharmacologic study that substance P causes epicardial coronary dilatation and increases coronary blood flow in humans.
